The Hintegra Total Ankle Replacement: survivorship, failure modes and patient reported outcomes in 70 consecutive cases with a minimum 5 year follow up
L. Clifton, A. Kingman, P. Rushton, A. Murty, R. Kakwani, J. Coorsh, D. Townshend
1Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom
2Northumbria Healthcare NHS Foundation Trust, Hexham, United Kingdom
3Northumbria Healthcare NHS Foundation Trust, Wansbeck, United Kingdom
Introduction: We report the functional outcome and survivorship of the Hintegra Total Ankle Replacement (TAR), in consecutive cases by multiple surgeons in a single UK institution. Between 2010-2014 the Hintegra TAR held 7.1% UK market share and surgeons should be aware of failure mechanisms.
Methods: We conducted a retrospective review of prospectively collected data for 70 consecutive Hintegra TAR cases in a single institution between 2010-2014. Data collected included patient demographics, complications, reoperations, patient reported outcome measures (PROMS: AOS, MOX-FQ, pain VAS) and patient satisfaction.
Results: The 70 patients (54 male/ 16 female) had an average age of 69 (range 48-84 years). Mean follow up was 76 months (range 60-104), 10 patients died during the follow up. Implant survivorship was 81.4% at most recent follow up. The commonest radiographic finding was periprosthetic cysts (n=28, 40%), size range (7-40mm), location of cysts: isolated talus (n=14), isolated tibia (n=6), mixed (n=8). 10 failed TARs were revised to Inbone TAR at a mean of 48 months (range 9-69). 3 Failed TARs were revised to arthrodesis (2 tibiotalar fusions, 1 hindfoot nail). 11 patients required reoperation with implant retention: 8 periprosthetic cyst debridement and grafting at a mean of 61 months (range 27-91), 1 lateral gutter debridement and 1 periprosthetic fracture ORIF. PROMS data was available for all patients. Overall patients showed marked improvement in functional outcome scores between pre-operative and final follow up questionnaires. Mean pre-op AOS: 62, MOX-FQ: 68 and pain VAS: 67.5 with mean final follow up scores of: AOS: 35, MOX-FQ: 36 and pain VAS: 30.
Conclusion: Our experience demonstrates improved PROMS following ankle arthroplasty for patients with a mean follow up of 6.4 years. Implant survivorship is similar to other TAR studies. We have identified a high incidence of periprosthetic cysts and would recommend ongoing surveillance of these patients.
Print
Click thumbnail below to view poster / thumbnail: